Skip to content

Arcutis Biotherapeutics

US · ARQT #2465 by market cap Listed 2020
26.36 -0.81 -2.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 28 in the most recent period (2026/Q3).
  • Total institutional ownership rose 13.7 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
121.52% +13.72pp
Institutions
367 +28
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund70.23%
Hedge Fund26.91%
VC/PE Fund10.44%
Public Company7.73%
Private Company3.24%
Government Pension Fund1.49%
Individual/Insider1.03%
Endowment Fund0.69%
Insurance Company0.40%
Sovereign Wealth Fund0.32%

Top holders as of 2026-09-30

BlackRock 15.16% · 19.17M sh
Montanova Capital, LLC 9.84% · 12.44M sh
Frazier Life Sciences Management, LP 7.81% · 9.87M sh
Rubric Capital Management LP 6.54% · 8.27M sh
State Street Global Advisors 6.10% · 7.72M sh
Polar Capital Holdings Plc 5.22% · 6.61M sh
UBS Asset Management 4.56% · 5.76M sh
Morgan Stanley 4.19% · 5.30M sh
Vanguard Capital Management, LLC 3.95% · 4.99M sh
D. E. Shaw & Co., L.P. 3.14% · 3.95M sh
Jennison Associates LLC 3.34% · 4.22M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 20 buys · 26 sells

NameRoleStake
Todd Watanabe Chief Executive Officer 0.50%
Christopher Peetz Independent Director 0.15%
Patrick Burnett Chief Medical Officer 0.09%
Latha Vairavan Senior VP & Chief Financial Officer 0.07%
Larry Edwards Former Executive Vice President 0.05%
Patrick Heron Independent Director 0.03%
Howard Welgus Independent Director 0.02%
Masaru Matsuda Executive Vice President 0.02%
Robert Andrew Scott Independent Director 0.01%
Keith Leonard Independent Chairperson 0.01%
Halley Gilbert Independent Director 0.01%
Neha Krishnamohan Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-03 Robert Lisicki Interim Executive VP & Chief Commercial Officer Initial Statement of Beneficial 0 --
2026-11-03 Masaru Matsuda Executive Vice President Derivative Exercise and Sale -40,000 $3.64–34.32
2026-11-01 Todd Watanabe Chief Executive Officer Open Market Disposition -4,377 $31.86
2026-11-01 Patrick Burnett Chief Medical Officer Open Market Disposition -943 $31.86
2026-11-01 Masaru Matsuda Executive Vice President Open Market Disposition -1,219 $31.86
2026-10-22 Robert Andrew Scott Independent Director Other Acquisition +2,819 --
2026-10-22 Robert Andrew Scott Independent Director Other Derivative Acquisition +29,170 $31.20
2026-10-22 Robert Andrew Scott Independent Director Initial Statement of Beneficial 0 --
2026-10-14 Howard Welgus Independent Director Automatic Disposition -634 $26.93
2026-10-14 Howard Welgus Independent Director Derivative Exercise and Sale -4,094 $6.52–26.93
2026-09-15 Masaru Matsuda Executive Vice President Open Market Disposition -3,674 $25.00
2026-09-14 Howard Welgus Independent Director Automatic Disposition -634 $24.18
2026-09-14 Howard Welgus Independent Director Derivative Exercise and Sale -4,096 $6.52–24.18
2026-09-07 Masaru Matsuda Executive Vice President Automatic Disposition -9,989 $25.03
2026-08-26 Terrie Curran Independent Director Derivative Exercise and Sale -38,200 $7.51–25.03
2026-08-19 Terrie Curran Independent Director Derivative Exercise and Sale -1,072 $7.51–26.04
2026-08-18 Patrick Burnett Chief Medical Officer Open Market Disposition -1,697 $27.00
2026-08-16 Howard Welgus Independent Director Automatic Disposition -634 $26.18
2026-08-16 Howard Welgus Independent Director Derivative Exercise and Sale -4,096 $6.52–26.18
2026-08-11 Patrick Burnett Chief Medical Officer Derivative Exercise and Sale -15,000 $3.64–26.52

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arcutis Biotherapeutics discussion 0 comments

Add a comment